Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?

Over 80% of CRS with Nasal Polyps’ Patients have Type 2 Inflammation Dupixent is the first and only biologic to inhibit il-4 and il-13 signaling in crs with nasal polyps.

Hear From An Expert On Identify Patients Who Are Appropriate Candidates For Biologic Treatment

On average the typical patients with nasal polyps have had +1 sinus surgery, sinus surgery dose not cure the nasal polyps. A medication where i can prevent revision sinus surgery...a good thing for me and for the patient.

Read article

Hear From An Expert On The Type 2 Immune Response And Inflammation

Read article

Nasal Polyps

Hear from an expert on what does Dupixent bring to your practice?

Read article

MAT-KW-2400275/V1/MAY2024